tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2025 Dec;21(1):2518644.
doi: 10.1080/21645515.2025.2518644. Epub 2025 Jun 28. Evaluating the effectiveness of COVID-19 vaccines during a period of Omicron variant predominance among Bangladeshi population: A test-negative design measurement
Md Taufiqul Islam[SUP] 1 [/SUP], Farhana Khanam[SUP] 1 [/SUP], Faisal Ahmmed[SUP] 1 [/SUP], Md Nazmul Hasan Rajib[SUP] 1 [/SUP], Md Ismail Hossen[SUP] 1 [/SUP], Shahinur Haque[SUP] 1 [/SUP], Prasanta Kumar Biswas[SUP] 1 [/SUP], Shah Ali Akbar Ashrafi[SUP] 2 [/SUP], Ahmed Nawsher Alam[SUP] 3 [/SUP], Mallick Masum Billah[SUP] 3 [/SUP], Monalisa[SUP] 3 [/SUP], Mohammed Ziaur Rahman[SUP] 1 [/SUP], Omar Hamza Bin Manjur[SUP] 4 [/SUP], Mohammad Tanbir Habib[SUP] 4 [/SUP], Mokibul Hassan Afrad[SUP] 1 [/SUP], S M Shamsuzzaman[SUP] 5 [/SUP], Ahmed Abu Saleh[SUP] 6 [/SUP], Mostafa Aziz Sumon[SUP] 7 [/SUP], Asif Rashed[SUP] 8 [/SUP], Tahmina Shirin[SUP] 3 [/SUP], John D Clemens[SUP] 9 10 [/SUP], Firdausi Qadri[SUP] 1 [/SUP]
Affiliations
The study was conducted to estimate the protective effectiveness (PE) of complete primary or booster dose regimens of COVID-19 vaccines deployed in Bangladesh. The study was conducted in four hospitals in Dhaka between December 30, 2021, and August 31, 2022 following a test-negative design. Patients aged ≥18 years attended with COVID-like symptoms were enrolled and tested for RT-PCR. Test-negative controls were matched to confirmed cases at a 1:1 ratio considering site, date, and age groups. Conditional logistic regression was used to estimate the PE considering the association between receipt of complete primary with or without a booster regimen and development of COVID-19 disease symptoms. Whole genome sequencing (WGS) was carried out to confirm the variants. RT-PCR positive 847 cases were matched to 847 controls. WGS of strains revealed 6% to be the Delta variant and 94% was Omicron variant. The PE conferred by receipt of complete primary regimen with or without booster dose of any vaccine revealed no significant protection (15%, 95% CI: -11 to 36, p = .23) against any COVID-19 disease or severe disease (14%, 95%CI: -23 to 39, p = .42). However, there was a protective association between receipt of complete primary regimen with or without booster dose of one mRNA vaccine (Pfizer-BioNTech) against any COVID-19 disease (88% (95% CI: 26 to 98, p = .023)) for the first 90 days. The analysis suggested little vaccine effectiveness during Omicron surge, with the possible exception of one mRNA-vaccine 90 days after dosing.
Keywords: Bangladesh; COVID-19 vaccines; omicron variant; test-negative design (TND) vaccine effectiveness.
. 2025 Dec;21(1):2518644.
doi: 10.1080/21645515.2025.2518644. Epub 2025 Jun 28. Evaluating the effectiveness of COVID-19 vaccines during a period of Omicron variant predominance among Bangladeshi population: A test-negative design measurement
Md Taufiqul Islam[SUP] 1 [/SUP], Farhana Khanam[SUP] 1 [/SUP], Faisal Ahmmed[SUP] 1 [/SUP], Md Nazmul Hasan Rajib[SUP] 1 [/SUP], Md Ismail Hossen[SUP] 1 [/SUP], Shahinur Haque[SUP] 1 [/SUP], Prasanta Kumar Biswas[SUP] 1 [/SUP], Shah Ali Akbar Ashrafi[SUP] 2 [/SUP], Ahmed Nawsher Alam[SUP] 3 [/SUP], Mallick Masum Billah[SUP] 3 [/SUP], Monalisa[SUP] 3 [/SUP], Mohammed Ziaur Rahman[SUP] 1 [/SUP], Omar Hamza Bin Manjur[SUP] 4 [/SUP], Mohammad Tanbir Habib[SUP] 4 [/SUP], Mokibul Hassan Afrad[SUP] 1 [/SUP], S M Shamsuzzaman[SUP] 5 [/SUP], Ahmed Abu Saleh[SUP] 6 [/SUP], Mostafa Aziz Sumon[SUP] 7 [/SUP], Asif Rashed[SUP] 8 [/SUP], Tahmina Shirin[SUP] 3 [/SUP], John D Clemens[SUP] 9 10 [/SUP], Firdausi Qadri[SUP] 1 [/SUP]
Affiliations
- PMID: 40580038
- DOI: 10.1080/21645515.2025.2518644
The study was conducted to estimate the protective effectiveness (PE) of complete primary or booster dose regimens of COVID-19 vaccines deployed in Bangladesh. The study was conducted in four hospitals in Dhaka between December 30, 2021, and August 31, 2022 following a test-negative design. Patients aged ≥18 years attended with COVID-like symptoms were enrolled and tested for RT-PCR. Test-negative controls were matched to confirmed cases at a 1:1 ratio considering site, date, and age groups. Conditional logistic regression was used to estimate the PE considering the association between receipt of complete primary with or without a booster regimen and development of COVID-19 disease symptoms. Whole genome sequencing (WGS) was carried out to confirm the variants. RT-PCR positive 847 cases were matched to 847 controls. WGS of strains revealed 6% to be the Delta variant and 94% was Omicron variant. The PE conferred by receipt of complete primary regimen with or without booster dose of any vaccine revealed no significant protection (15%, 95% CI: -11 to 36, p = .23) against any COVID-19 disease or severe disease (14%, 95%CI: -23 to 39, p = .42). However, there was a protective association between receipt of complete primary regimen with or without booster dose of one mRNA vaccine (Pfizer-BioNTech) against any COVID-19 disease (88% (95% CI: 26 to 98, p = .023)) for the first 90 days. The analysis suggested little vaccine effectiveness during Omicron surge, with the possible exception of one mRNA-vaccine 90 days after dosing.
Keywords: Bangladesh; COVID-19 vaccines; omicron variant; test-negative design (TND) vaccine effectiveness.